OpenAI Researcher Launches AI Drug Discovery Startup
Miles Wang leaves OpenAI to start a new venture focused on AI-driven drug discovery.
1Miles Wang's New Venture
OpenAI researcher Miles Wang is launching a new startup to accelerate drug discovery using AI models. Wang is leaving OpenAI to focus on this new project and is expected to bring several researchers with him.
2Investor Interest
Wang's startup aims to raise $200 million at a $2 billion valuation. Lightspeed is leading this funding round, highlighting the potential of AI in life sciences.
3Competing Ventures
AI-driven drug discovery startups like Chai Discovery and Isomorphic Labs have also secured significant investments recently, showcasing the competition and growth potential in the sector.
4AI's Role in Drug Discovery
AI models predict molecular interactions to speed up the discovery of new drugs. Additionally, finding new uses for FDA-approved drugs is a major advantage of this technology.
5Wang's Background
Miles Wang left Harvard to join OpenAI, where he conducted research on AI models that automate scientific discovery. Investor confidence in young entrepreneurs also supports Wang's project.
6Future Expectations
AI-driven drug discovery has the potential to revolutionize life sciences. Wang's venture could be a significant step forward, accelerating innovations in the industry.
Original article: TechCrunch — OpenAI Araştırmacısı AI İlaç Keşfi Girişimi Kuruyor